Immunic reports successful 2023 and prepares for key 2025 milestones

Immunic reports successful 2023 and prepares for key 2025 milestones

–News Direct–

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023.

Outlining the company's achievements, Dr Vitt noted the company strengthened its balance sheet by raising up to $240 million. The first tranche of the three tranche private placement is expected to extend the company's cash runway into the third quarter of 2025, beyond important clinical readouts for its Phase 2 study in progressive multiple sclerosis (MS), known as the CALLIPER study, with results anticipated in April 2025.

Clinically, Immunic achieved positive results across its portfolio, including its Vidofludimus calcium and IMU-856. Dr Vitt said vidofludimus calcium showed promising phase 2 interim results in 2023, including a significant reduction in NfL biomarkers in patients with progressive MS, indicating its potential as a unique treatment option. IMU-856, targeting gastrointestinal disorders, demonstrated effectiveness in improving gut function in celiac disease patients, with results published in spring 2023.

Looking ahead to 2024, he said the focus is on preparing for the CALLIPER study readout in April 2025 and exploring further studies for IMU-856 in additional indications. The company continues discussions with potential pharmaceutical partners for its programs.

Contact Details

Proactive North America

Proactive North America

+1 604-688-8158

View source version on

Immunic Inc

comtex tracking


Post Disclaimer

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No DigiShor journalist was involved in the writing and production of this article.